Press Room

Article / May 04, 2004

Do we really need more trade-shows

BioFine Berlin, 4 May 2004

Hovione will be in at the 1st BioFine event in Berlin, so yes we did feel there was space for another show. In fact our thoughts are that some shows may have become too large and far too expensive, trying to be all things to all people, and with their gigantic size working against some of their users. Many of us, tired and with sore feet, wonder why we have to stand in queues waiting for expensive average food. We are looking at Bio-fine as a differentiated show - one that focuses away from commodities and is sensitive to pairing customers with suppliers eager to provide service and know-how.

In giving our best wishes to the managers of BioFine, we would remind them that this is a global industry where English is the lingua franca and the outlook is international. We all have full agendas and tight schedules so please do choose venues where foreigners are welcome, taxis cheap and plentiful, airports near-by and hotels at the convention centre and not a wet 5 (in fact 15) minute walk away! Please time your shows away from other well-established and popular industry events, do consider traditional holidays of the key nations involved, keep away from locations in seasons that are predictably wet and cold. A great show was CPhI 1997 in London in Earl´s Court - everyone spoke English, the walk to the tube was 2 minutes, it was sunny September, and close to all the hotels.

If Bio-fine wants to do really well look to how organisers of US shows do it. Food is free, no queues, no wet walks - and it is inexpensive. Charging attendees makes sure the quality stays high; keeping it small and with a smart market positioning makes sure the right people show up, business is done and time is not wasted. Going forward, security concerns are also a factor, keeping away from big crowds or major cities may be a plus.

At BioFine we will be offering our customers the latest technology we have added to our capabilities: particle size design, from lab to large-scale, with a focus on reproducibility of physical characteristics. Our customers tell us that the galenic interface is where most of our competitors fail. We are doing for particle size and crystal form what we did for injectable grade APIs in the 90´s, becoming a leader and defining bench-marks.

Guy Villax
CEO Hovione
Loures, 4th May 2004

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024